• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical ResearchInhibrx Biosciences
    Picture of Inhibrx Biosciences logo

    INBX — Inhibrx Biosciences News Story

    $90.500.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    • Market Cap
      $1.33bn
    • Enterprise Value
      $1.37bn
    • Revenue
      $1.30m
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • INBX Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    INBX Dividends
    All News

    NASDAQ RESUMED AT 08:00 AM

    Picture of Inhibrx Biosciences logoInhibrx Biosciences
    08/09/2026 13:00
    NASDAQ RESUMED  AT 08:00 AM

    Recent news on Inhibrx Biosciences

    See all news
    • Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)

      08/09/2026 18:21
    • Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

      08/09/2026 13:17
    • NASDAQ RESUMED AT 08:00 AM

      08/09/2026 13:00
    • Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study

      08/09/2026 12:41
    • NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

      08/09/2026 12:25

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.